Last reviewed · How we verify

NCT04589923

The VISION-Acute Study

Completed Last updated 20 July 2022
What this trial tests

trial testing Lifelight® Data Collect Blood Pressure Group in Hypertension in 127 participants. Completed in 7 May 2022.

Timeline
14 September 2020
Primary endpoint
29 April 2021
7 May 2022

Quick facts

Lead sponsorXim Limited
StatusCompleted
Study typeOBSERVATIONAL
Enrollment127
Start date14 September 2020
Primary completion29 April 2021
Estimated completion7 May 2022
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Xim Limited

Who can join

18 and older, any sex, with Hypertension or Hypoxia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

AIM: We propose an innovative approach using Lifelight® smart technology that will enable the continued provision of high level patient care at the same time as reducing pressure on nursing and equipment resources. METHOD : Lifelight® is a computer program ("app") which can be used on smart devices that contain a camera. It is able to measure all of the vital signs by measuring very small changes in skin colour that occur each time the heart beats. This means that it does not need to touch the patient. We believe this could be an effective way of measuring vital signs, especially during the COVID-19 pandemic when prevention of cross-contamination between patients is essential. Patients are also likely to be reassured by a contactless approach. During this study, we will recruit two groups of people who are hospitalised with an acute illness. The first group will be people expected to have abnormal blood oxygen levels such as those with acute respiratory problems including those with COVID-19. The second group will be people expected to have abnormal blood pressure. These Lifelight vital signs will be compared to measurements from standard clinical equipment. The exact number of participants recruited will depend on how quickly the app "learns" and how many of the vital signs collected are outside of the normal range. For the first group of participants, we will use a camera to collect data about the changes in their face and use this to teach the app how to measure blood oxygen level and also to check how well the app measures blood oxygen level, heart rate and respiratory rate. For the second group of participants, we will use a camera to collect data about the changes in their face to check how well the app measures blood pressure and respiratory rate. All of the data will be kept secure and participants will not be able to be identified.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Hypertension and COVID-19: Updates from the era of vaccines and variants.
    Swamy S, Koch CA, Hannah-Shmouni F, Schiffrin EL, et al · · 2022 · cited 10× · PMID 34900602 · DOI 10.1016/j.jcte.2021.100285
  2. Measurement of Vital Signs Using Lifelight Remote Photoplethysmography: Results of the VISION-D and VISION-V Observational Studies.
    Heiden E, Jones T, Brogaard Maczka A, Kapoor M, et al · · 2022 · cited 9× · PMID 36374541 · DOI 10.2196/36340

Verify or expand the search:

Other recruiting trials for Hypertension

Currently open trials in the same condition.

Other Xim Limited trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04589923.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing